XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non- Controlling Interest
Total
Balance at Sep. 30, 2023 $ 6,354 $ 253,056,133 $ (162,231,379) $ 90,831,108 $ 600,380 $ 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Issuance of common stock for services $ 4 76,142 76,146 76,146
Issuance of common stock for services (in Shares)   4,351          
Stock-based compensation expense 3,058,185 3,058,185 3,058,185
Net loss (9,231,185) (9,231,185) (9,231,185)
Balance at Dec. 31, 2023 $ 6,358 256,190,460 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   6,358,722          
Balance at Sep. 30, 2023 $ 6,354 253,056,133 (162,231,379) 90,831,108 600,380 91,431,488
Balance (in Shares) at Sep. 30, 2023   6,354,371          
Net loss             (28,348,675)
Balance at Jun. 30, 2024 $ 7,229 276,256,724 (190,580,054) 85,683,899 600,380 86,284,279
Balance (in Shares) at Jun. 30, 2024   7,229,016          
Balance at Dec. 31, 2023 $ 6,358 256,190,460 (171,462,564) 84,734,254 600,380 85,334,634
Balance (in Shares) at Dec. 31, 2023   6,358,722          
Issuance of common stock for services $ 6 98,073 98,079 98,079
Issuance of common stock for services (in Shares)   5,069          
Stock-based compensation expense 3,078,392 3,078,392 3,078,392
Net loss (8,544,154) (8,544,154) (8,544,154)
Balance at Mar. 31, 2024 $ 6,364 259,366,925 (180,006,718) 79,366,571 600,380 79,966,951
Balance (in Shares) at Mar. 31, 2024   6,363,791          
Issuance of common stock for services $ 6 109,944 109,950 109,950
Issuance of common stock for services (in Shares)   6,000          
Issuance of common stock in registered direct offering, net of costs of $1,281,051 $ 857 13,718,094 13,718,951 13,718,951
Issuance of common stock in registered direct offering, net of costs of $1,281,051 (in Shares)   857,143          
Issuance of common stock upon cashless exercise of stock options $ 2 (2)
Issuance of common stock upon cashless exercise of stock options (in Shares)   2,082          
Stock-based compensation expense 3,061,763 3,061,763 3,061,763
Net loss (10,573,336) (10,573,336) (10,573,336)
Balance at Jun. 30, 2024 $ 7,229 276,256,724 (190,580,054) 85,683,899 600,380 86,284,279
Balance (in Shares) at Jun. 30, 2024   7,229,016          
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Issuance of common stock, net of costs $ 480 2,573,571 2,574,051 2,574,051
Issuance of common stock, net of costs (in Shares)   480,000          
Stock-based compensation expense 2,524,824 2,524,824 2,524,824
Net loss (10,281,246) (10,281,246) (10,281,246)
Net loss attributable to non-controlling interest 513,000 513,000 (513,000)
Balance at Dec. 31, 2024 $ 7,727 276,538,816 (211,138,464) 65,408,079 3,511,380 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243          
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Net loss             (30,996,623)
Balance at Jun. 30, 2025 $ 14,475 295,888,916 (230,844,841) 65,058,550 2,502,380 67,560,930
Balance (in Shares) at Jun. 30, 2025   14,475,029          
Balance at Dec. 31, 2024 $ 7,727 276,538,816 (211,138,464) 65,408,079 3,511,380 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243          
Issuance of common stock, net of costs $ 1,034 3,464,773 3,465,807 3,465,807
Issuance of common stock, net of costs (in Shares)   1,033,406          
Stock-based compensation expense 2,702,031 2,702,031 2,702,031
Net loss (11,511,505) (11,511,505) (11,511,505)
Net loss attributable to non-controlling interest 595,000 595,000 (595,000)
Balance at Mar. 31, 2025 $ 8,761 282,705,620 (222,054,969) 60,659,412 2,916,380 63,575,792
Balance (in Shares) at Mar. 31, 2025   8,760,649          
Issuance of common stock, net of costs $ 2,185 3,292,261 3,294,446 3,294,446
Issuance of common stock, net of costs (in Shares)   2,185,249          
Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 $ 465 1,743,292 1,743,757 1,743,757
Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 (in Shares)   465,000          
Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 $ 540 5,430,296 5,430,836 5,430,836
Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 (in Shares)   540,000          
Issuance of common stock upon exercise of pre-funded warrants $ 2,524 (2,227) 297 297
Issuance of common stock upon exercise of pre-funded warrants (in Shares)   2,524,131          
Sale of Series A preferred stock 100 100 100 100
Redemption of Series A preferred stock (100) (100) (100) (100)
Stock-based compensation expense 2,719,674 2,719,674 2,719,674
Net loss (9,203,872) (9,203,872) (9,203,872)
Net loss attributable to non-controlling interest 414,000 414,000 (414,000)
Balance at Jun. 30, 2025 $ 14,475 $ 295,888,916 $ (230,844,841) $ 65,058,550 $ 2,502,380 $ 67,560,930
Balance (in Shares) at Jun. 30, 2025   14,475,029